Effector Therapeutics
OverviewSuggest Edit
Effector Therapeutics is pioneering the discovery and development of selective translation regulators as a new class of small molecule therapeutics for cancer and other serious diseases.
| Type | Private | |
| Founded | 2012 | |
| HQ | San Diego, US | Map |
| Website | effector.com |
Recent NewsAll News
- eFFECTOR Presents Data on its Selective Translation Regulators at AACR 2019 Annual Meeting
- Research Published in Nature Medicine Demonstrates the Immunological Effects of Tomivosertib, Including Inhibiting Production of Checkpoint Protein PD-L1 and Increasing T Cell Infiltration into Tumors
- eFFECTOR Initiates Dosing in Phase 2 Trial of Tomivosertib (eFT508) in Advanced Castrate-Resistant Prostate Cancer (CRPC)
- Data Presented at AACR Special Conference on PI3K/mTOR Signaling Demonstrates Potential of eFFECTOR’s eIF4E Inhibitors in Cancer
Latest Updates
| Employees (est.) (Sept 2020) | 28 | (+8%) |
| Cybersecurity rating | A | More |
Key People/Management at Effector Therapeutics
Larry Lasky
Director
Simeon George
Director
Steve Worland
President and Chief Executive Officer, Director
Premal Patel
Chief Medical Officer
Denis Patrick
Director
Mark Densel
Vice President, Development Operations
Effector Therapeutics Office Locations
Effector Therapeutics has an office in San Diego
San Diego, US (HQ)
11180 Roselle St
Effector Therapeutics Financials and Metrics
Summary Metrics
Founding Date | 2012 |
Effector Therapeutics total Funding | $101 m |
Effector Therapeutics latest funding size | $16 m |
Time since last funding | 5 years ago |
Effector Therapeutics investors | U.S. Venture Partners (USVP), Osage University Partners, SR One, Novartis Venture Fund, Altitude Life Science Ventures, Astellas Venture Management, Abingworth, The Column Group, Mission Bay Capital, AbbVie Biotech Ventures |
Effector Therapeutics's latest funding round in February 2016 was reported to be $16 m. In total, Effector Therapeutics has raised $101 m
Effector Therapeutics Cybersecurity Score
Effector Therapeutics Online and Social Media Presence
Effector Therapeutics's Trends
Effector Therapeutics Blogs
January 14, 2019
Research Published in Nature Medicine Demonstrates the Immunological Effects of Tomivosertib, Including Inhibiting Production of Checkpoint Protein PD-L1 and Increasing T Cell Infiltration into Tumors
SAN DIEGO, January 14, 2019 – eFFECTOR Therapeutics, Inc., a leader in the development of selective translation regulators (STRs) for the treatment of cancer, today announced publication in the peer reviewed journal Nature Medicine of preclinical research demonstrating that tomivosertib (eFT508), th…
December 11, 2018
eFFECTOR Initiates Dosing in Phase 2 Trial of Tomivosertib (eFT508) in Advanced Castrate-Resistant Prostate Cancer (CRPC)
SAN DIEGO, CA — December 11, 2018 — eFFECTOR Therapeutics, Inc., (eFFECTOR), a leader in the development of selective translation regulators (STRs) for the treatment of cancer, announced today that it has dosed the first patient in a Phase 2 trial of tomivosertib (eFT508) in men with advanced castra…
December 03, 2018
Data Presented at AACR Special Conference on PI3K/mTOR Signaling Demonstrates Potential of eFFECTOR’s eIF4E Inhibitors in Cancer
SAN DIEGO, December 3, 2018 — eFFECTOR Therapeutics, Inc., (eFFECTOR), a leader in the development of selective translation regulators (STRs) for the treatment of cancer, announced today that it presented data on Sunday, December 2 at the AACR Special Conference on PI3K/mTOR Signaling demonstrating …
October 16, 2018
eFFECTOR Therapeutics Announces Clinical Collaboration with Merck to Conduct a Phase 2 Combination Trial to Evaluate eFFECTOR’s Tomivosertib (eFT508) with KEYTRUDA® (pembrolizumab) for Metastatic Triple Negative Breast Cancer
SAN DIEGO, October 16, 2018 - eFFECTOR Therapeutics, Inc., a leader in the development of selective translation regulators (STRs) for the treatment of cancer, today announced it has entered into a clinical collaboration agreement with Merck (known as MSD outside the United States and Canada)
July 27, 2018
eFFECTOR Initiates Dosing of eFT508 (tomivosertib) in a Phase 2 Add-on (CPI-A) Trial in Combination with Checkpoint Inhibitors to Treat Patients with Insufficient Response to Checkpoint Inhibitors Alone
SAN DIEGO, July 27, 2018 -- eFFECTOR Therapeutics, Inc., a leader in the development of selective translation regulators (STRs) for the treatment of cancer, today announced that it has dosed the first patient in a Phase 2 clinical trial of eFT508 (tomivosertib), the company’s oral, small molecule in…
Effector Therapeutics Frequently Asked Questions
When was Effector Therapeutics founded?
Effector Therapeutics was founded in 2012.
Who are Effector Therapeutics key executives?
Effector Therapeutics's key executives are Larry Lasky, Simeon George and Steve Worland.
How many employees does Effector Therapeutics have?
Effector Therapeutics has 28 employees.
Who are Effector Therapeutics competitors?
Competitors of Effector Therapeutics include Aptevo Therapeutics, Geron and Aeglea Biotherapeutics.
Where is Effector Therapeutics headquarters?
Effector Therapeutics headquarters is located at 11180 Roselle St, San Diego.
Where are Effector Therapeutics offices?
Effector Therapeutics has an office in San Diego.
How many offices does Effector Therapeutics have?
Effector Therapeutics has 1 office.
Learn about Craft real-time company insights
Receive alerts for 300+ data fields across thousands of companies